Litigation Details for Securities and Exchange Commission v. Lemelson (D. Mass. 2018)
✉ Email this page to a colleague
Securities and Exchange Commission v. Lemelson (D. Mass. 2018)
| Docket | ⤷ Start Trial | Date Filed | 2018-09-12 |
| Court | District Court, D. Massachusetts | Date Terminated | 2022-03-30 |
| Cause | 12:22 Securities Fraud | Assigned To | Patti B. Saris |
| Jury Demand | Both | Referred To | |
| Parties | GREGORY LEMELSON; SECURITIES AND EXCHANGE COMMISSION | ||
| Patents | 6,066,339; 7,160,870; 7,232,818; 7,332,481; 7,417,042; 7,452,874; 7,473,686; 7,491,704; 7,547,719; 7,635,773; 7,737,112; 7,790,704; 7,795,293; 8,052,993; 8,052,994; 8,052,995; 8,062,665; 8,071,129; 8,129,346; 8,207,125; 8,207,126; 8,207,127; 8,207,297; 8,410,077 | ||
| Attorneys | Alfred A. Day; Jason M. Strojny | ||
| Firms | Dla Piper LLP (Us); Securities and Exchange Commission | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Securities and Exchange Commission v. Lemelson
The small molecule drugs covered by the patents cited in this case are ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , and ⤷ Start Trial .
Details for Securities and Exchange Commission v. Lemelson (D. Mass. 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2018-09-12 | External link to document | |||
| 2018-09-12 | 261 | Exhibit V | Type of Protection U.S. 6,066,339 Nov. 25, 2017…have filed patent applications and received patents that conflict with patents or patent applications… various patents. The nominal patent expiration dates have been provided. The actual patent term may… Patents and pending patent applications covering Captisol are owned by Ligand. Other patents and …cease when the relevant patent expires. Our high purity patents, U.S. Patent Nos. 7,635,773 and 8,410,077 | External link to document |
| 2018-09-12 | 86 | Exhibit 19 | when the relevant patent expires. Our high purity patents, U.S. Patent Nos. 7,635,773 and 8,410,077 and… have filed patent applications and received patents that conflict with patents or patent applications…products or processes that are patentable. Even if we do obtain patents, such patents may not adequately protect… to expire until 2029 and our morphology patents, U.S. Patent Nos. 7,629,331 and 8,049,003 and foreign…resulting from the patent rights of others could significantly reduce the coverage of our patents and limit our | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
